PCRX logo

PACIRA BIOSCIENCES INC

PCRXNASDAQ
🏆 #2483 by market capEarnings Nov 4US Equity
$173.34▲ $12.97 (+7.48%)
Simulated price
🔔
Track PCRX
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 7.5%
7d—
14d—
30d—
ytd—
1y—
🏦Market Cap
$988M
Small Cap
📈Revenue Growth (YoY)
+3.6%
Slowing
📊Gross Margin
79.2%
High
💵FCF Margin
24.1%
Strong
⚖️P/S Ratio
1.3x
Cheap
Otter Score
72
Fair
No chart data available for PCRX.

Trading Snapshot

Day Range
$171.62 – $174.32
52-Week Range
$18.80 – $27.66
Volume
$1.93B
Avg Volume
$2.27B
Shares Outstanding
39.3M
Next Earnings
Nov 4, 2026

Fundamentals Snapshot

Annual Revenue
$726M
Last Q Revenue
$192M
P/E Ratio
71.3
P/S Ratio
1.3x
EPS (TTM)
$0.37
Dividend Yield
0.00%
Dilution (1yr)
−12.3%

Why Investors Own PCRX

  • ✓High-growth profile — revenue up +4.4% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 75% gross margin and 22% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

PCRX logo

PACIRA BIOSCIENCES INC

PCRX
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$726M▲ +3.6% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
79.4%▲ +4.9% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$33M▼ −145.4% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$137M▼ −23.5% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
43.0M▼ −12.3% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
−$296M▲ +$66M YoY
StockOtter · stockotter.space

About PACIRA BIOSCIENCES INC

Operating within the United States, Pacira BioSciences, Inc. is dedicated to providing healthcare professionals and their patients with non-opioid solutions for pain management and regenerative health. Its offerings include EXPAREL, an injectable liposomal bupivacaine suspension, and ZILRETTA, an extended-release injectable suspension of triamcinolone acetonide. Furthermore, the company offers the iovera system, a non-opioid, handheld cryoanalgesia device capable of delivering precisely controlled cold temperatures to targeted nerves. Pacira also develops its unique multivesicular liposome (MVL) drug delivery technology, which encapsulates therapeutic compounds while preserving their inherent molecular structure. Established in 2006, the firm was formerly known as Pacira Pharmaceuticals, Inc. until its name change to Pacira BioSciences, Inc. in April 2019. Its main corporate office is situated in Tampa, Florida.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
72/100

Analyst Price Target

ⓘ
Average Target
$231.45
▲ +33.5% Upside
High Target$289.31
Low Target$178.96
Based on 22 analysts

Latest News & Updates

🚀
Barron’s·2h ago

PACIRA BIOSCIENCES INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Barron’s·5h ago

Analysts lift PCRX price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Reuters·1d ago

PACIRA BIOSCIENCES INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.